(pre-print): Methodological issues for using a common data model of COVID-19 vaccine uptake and important adverse events of interest

March 2022: A pre-print article examining at whether a common data model could be used to help pool data from across the four UK nations to investigate the national uptake of COVID-19 vaccines, as well as monitor the frequency of rare adverse events of interest (AEIs), such as CVST and anaphalaxis, that may occur post-vaccination.

Methodological issues for using a common data model (CDM) of COVID-19 vaccine uptake and important adverse events of interest (AEIs): the Data and Connectivity COVID-19 Vaccines Pharmacovigilance (DaC-VaP) United Kingdom feasibility study.

Delanerolle, G.; Williams, R.; Stipancic, A.; de Lusignan, S.; et. al.

JMR Formative Research

Published on: 08 March 2022

Available at: https://preprints.jmir.org/preprint/37821 

Note

This is a pre-print article that has not yet been peer reviewed. This article has been accepted, and will later be published as a formal peer-reviewed article.

Peer Review Article Published

This article has now been peer reviewed and published in JMIR Formative Research. If you would like to find out more, read our plain English summary for this paper by clicking the link down below.

Read: plain English summary of peer reviewed article

This article was published on